Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 16Withdrawn 2Recruiting 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lung Neoplasms 9Leukemia, Myeloid, Acute 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 7Clear-cell metastatic renal cell carcinoma 5Prostatic Neoplasms 4Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Glioblastoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphatic System Neoplasm 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Specimen Handling × Clear all
NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡